Professor Robert Carlisle

Robert Carlisle is an Associate Professor within the Institute of Biomedical Engineering (IBME) at the University of Oxford and a PI on OXCD3. He completed a PhD in gene therapy before performing post-doctoral work within the Department of Oncology at the University of Oxford investigating mechanisms to enhance the bloodstream stability of viral vectors. This was the beginning of his fascination with the challenge of how to improve the tumour delivery of anti-cancer therapies, especially the biologic agents which offer the most promise. A combined project with members of the IBME revealed the potential of physical stimuli to provide a solution to this problem. His subsequent transition to the IBME has allowed him to contribute to work which is now the focus of a Clinical Trial (TARDOX) and successful commercialisation ( His team continues to work with a range of therapeutics across a range of applications including transdermal as well as tumour delivery. He has published over 40 peer reviewed papers, is named on 3 patents and presented at numerous conferences. He is also the associate director of the CDT in Synthetic Biology and the Director of the MSc in nanotechnology for Medicine and Health care at Oxford University. 

© Copyright OXCD3 2016